Literature DB >> 19116183

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain.

Ramez Ghanbari1, Mostafa El Mansari, Mohammed Shahid, Pierre Blier.   

Abstract

Asenapine is a psychopharmacologic agent being developed for schizophrenia and bipolar disorder. This study electrophysiologically characterized the in vivo effects of asenapine at dorsal raphe nucleus (DRN) and hippocampus serotonin-1A (5-HT(1A)), ventral tegmental area D(2), locus coeruleus 5-HT(2A,) and alpha(2)-adrenergic receptors in anesthetized rats. Asenapine displayed potent antagonistic activity at alpha(2)-adrenoceptors (ED(50), 85+/-2 microg/kg), 5-HT(2A) (ED(50), 75+/-2 microg/kg) and D(2) receptors (ED(50), 40+/-2 microg/kg) as evidenced by its reversal of clonidine-, DOI-, and apomorphine-induced inhibition of norepinephrine and dopamine neurons. In contrast, asenapine acted as a partial agonist at 5-HT(1A) receptors in DRN and hippocampus, as indicated by blockade of its inhibitory effect on neuronal firing by the 5-HT(1A) antagonist WAY 100635 and the partial inhibition of the suppressant action of 5-HT when co-applied by microiontophoresis. These results confirm that asenapine displays potent antagonistic activity at 5-HT(2A), D(2), alpha(2)-adrenergic receptors and provide evidence to support its 5-HT(1A) partial agonistic activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116183     DOI: 10.1016/j.euroneuro.2008.11.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

2.  Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism.

Authors:  Shikha Snigdha; Nagi Idris; Ben Grayson; Mohammed Shahid; Jo C Neill
Journal:  Psychopharmacology (Berl)       Date:  2010-11-19       Impact factor: 4.530

Review 3.  Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.

Authors:  Claudine M Chwieduk; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

4.  Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission.

Authors:  Sarah Delcourte; Erika Abrial; Adeline Etiévant; Renaud Rovera; Jørn Arnt; Michael Didriksen; Nasser Haddjeri
Journal:  CNS Neurosci Ther       Date:  2017-04-17       Impact factor: 5.243

5.  Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine.

Authors:  Gavin P Reynolds
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

Review 6.  Asenapine.

Authors:  Juliane Weber; Paul L McCormack
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

7.  Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.

Authors:  Olivia Frånberg; Monica M Marcus; Vladimir Ivanov; Björn Schilström; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2009-02-07       Impact factor: 4.530

8.  Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder.

Authors:  Jodi M Gonzalez; Peter M Thompson; Troy A Moore
Journal:  Patient Prefer Adherence       Date:  2011-07-01       Impact factor: 2.711

9.  Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.

Authors:  Carl Björkholm; Olivia Frånberg; Anna Malmerfelt; Monica M Marcus; Åsa Konradsson-Geuken; Björn Schilström; Kent Jardemark; Torgny H Svensson
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder.

Authors:  Delia Bishara; David Taylor
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.